Latest:
Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL
Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ari VanderWalde, MD
Latest:
Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021
Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.
Arie Dosoretz MD
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation
Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Arie P. Dosoretz, MD
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Ariel E. Marciscano, MD
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Arjun V. Balar, MD
Latest:
Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC
Arjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).